airoi.org

AIROI - Artificial Intelligence Return on Invest
The AI strategy for decision-makers and managers

Business excellence for decision-makers & managers by and with Sanjay Sauldie

AIROI - Artificial Intelligence Return on Invest: The AI strategy for decision-makers and managers

AIROI - Artificial Intelligence Return on Invest: The AI strategy for decision-makers and managers

Start » PharmaInnovation: Chemistry & Pharma rethought for decision-makers
11 September 2026

PharmaInnovation: Chemistry & Pharma rethought for decision-makers

4.4
(431)

Why are established companies in the chemical and pharmaceutical industries losing touch with agile start-ups—which seem to appear out of nowhere and revolutionise entire market segments within a few years—despite billion-pound investments?

This question occupies decision-makers in boardrooms and development departments alike, because the answer to it determines the future viability of entire corporations. The area PharmaInnovation: Chemistry & Pharma reimagined faces fundamental change that challenges traditional business models while simultaneously opening up unprecedented opportunities. At a time when molecules are being discovered through intelligent algorithms and production processes are self-optimising, leaders must fundamentally rethink their strategic direction. The following discussion offers you profound insights into processes of change that are already setting the course for tomorrow, and demonstrates concrete ways in which you can successfully navigate your company through this transformative phase.

The realigning of the value chain in the pharma innovation sector

The classical value chain in the pharmaceutical and chemical industry is currently undergoing a profound transformation that goes far beyond incremental improvements and is shaking the foundations of established processes. Companies such as BASF have recognised that the integration of digital technologies into research and development is no longer optional, but has become an existential necessity. The combination of laboratory automation and machine learning makes it possible to identify synthetic pathways that might have remained hidden from human researchers. Bayer, for example, relies on automated high-throughput screening methods that can test thousands of candidate molecules daily. Novartis has fundamentally transformed its drug discovery through predictive modelling and is achieving remarkable successes.

However, the changes affect more than just research. Production is also experiencing a fundamental upheaval. Continuous manufacturing processes are increasingly replacing traditional batch production. This so-called continuous manufacturing not only significantly reduces production times, but also improves quality control. Pfizer has already converted several production lines to continuous processes. Roche is investing heavily in modular production facilities. Merck is developing flexible manufacturing concepts for personalised medicines.

Best practice with a AIROI customer

A medium-sized pharmaceutical company from southern Germany was faced with the challenge of fundamentally modernising its decades-old development processes without losing the valuable accumulated experience of its long-standing employees. As part of a transruption coaching engagement, we first analysed the existing structures and, together with the management team, identified the greatest points of friction in the process chain. It turned out that communication between research and production had significant shortcomings, leading to unnecessary delays in the market launch of new products. Through the implementation of cross-functional teams and the introduction of agile project methods, the time to market was reduced by a remarkable forty percent. Employees reported significantly improved collaboration and an increased commitment to innovation projects. The combination of structural changes and individual support for managers through our coaching programme proved particularly valuable. The company was able to sustainably strengthen its competitive position and is now regarded as a pioneer in its market segment.

Digital twins and simulation methods as drivers of pharmaceutical innovation: chemistry & pharma rethought

The development of digital twins has triggered a revolution in the chemical and pharmaceutical industries, the significance of which is still underestimated by many decision-makers. These virtual replicas of real production plants make it possible to test process optimisations risk-free and predict how changes will impact overall performance. Siemens, together with leading pharmaceutical manufacturers, has developed digital twins that map complete production lines. Simulation accuracy has now reached impressive levels of over ninety-five per cent.

Evonik is deploying digital twins to maximise the yield of speciality chemicals. Lonza uses simulation methods to optimise biotechnological processes. AstraZeneca has mapped its entire supply chain digitally and can now proactively identify bottlenecks. This development clearly shows just how important the fusion of the physical and digital worlds has become. Companies that ignore these technologies risk a significant competitive disadvantage.

The integration of real-time data into simulation models opens up entirely new possibilities for process control. Sensors continuously capture parameters such as temperature, pressure and flow rates. This data flows directly into the digital models, enabling immediate adjustments. Johnson & Johnson has implemented this approach in several plants. Boehringer Ingelheim reports significant quality improvements through predictive process control. Sanofi uses real-time analytics to minimise scrap rates.

Personalised medicine and its impact on production strategies

The trend towards personalised medicine presents the pharmaceutical industry with entirely new challenges that fundamentally question traditional mass production concepts. When therapies are tailored to individual genetic profiles, production systems must also become more flexible and scalable. CAR-T cell therapies from Novartis and Kite Pharma serve as prime examples of how individualised treatments change the value chain. Each therapy is manufactured for a single patient, which brings entirely new logistical requirements.

Bristol Myers Squibb has established specialised manufacturing centres for personalised therapies. Gilead is investing in decentralised manufacturing capacities close to clinical centres. Takeda is developing modular production units that can be rapidly deployed at various locations. These developments require a fundamental rethink among decision-makers who have previously relied on economies of scale through mass production.

Best practice with a AIROI customer

An internationally active speciality chemicals manufacturer approached us because it had recognised that its innovation cycles were significantly too long compared to emerging competitors. The transruptions coaching support began with a comprehensive analysis of the innovation culture and existing decision-making paths, which were frequently slowed down by hierarchical structures. Together with the management team, we developed a new governance model that enabled faster decisions in innovation projects without neglecting the necessary diligence regarding regulatory requirements. The establishment of an innovation lab as a protected space for experimental approaches proved particularly successful and was enthusiastically received by employees. Within eighteen months, the company was able to bring three new products to market maturity that had previously stagnated in development. The managers reported a tangible cultural shift towards a greater appetite for experimentation and a constructive approach to mistakes, which positively influenced the entire company.

Sustainability as a strategic imperative in the context of pharmaceutical innovation

The demand for sustainable production methods is long no longer a fringe issue, but is moving to the centre of strategic decisions for executives across the entire industry. Chemical and pharmaceutical companies are under growing pressure to improve their environmental performance while remaining economically successful. DSM has committed to complete climate neutrality and is fundamentally transforming its production processes. Henkel is developing bio-based alternatives to petrochemical raw materials with remarkable success.

BASF is investing billions in green chemistry and developing catalytic processes that drastically reduce energy requirements. Covestro is focusing on the circular economy and increasingly using recycled raw materials in its production processes. Wacker Chemie is researching biotechnological synthesis routes as an alternative to conventional chemical processes. These initiatives show that sustainability and economic success no longer have to be opposites.

The regulatory frameworks are significantly intensifying this trend. The European Green Deal initiative is setting ambitious targets for the chemical industry. Pharmaceutical companies increasingly have to document the environmental impact of their products over their entire lifecycle. GSK has launched a programme to reduce water consumption in active pharmaceutical ingredient production. Eli Lilly is optimising synthesis routes to minimise solvent consumption. AbbVie is developing packaging concepts from renewable raw materials.

Cooperation models and open innovation

The increasing complexity of innovation processes makes it impossible even for large corporations to maintain all the necessary competencies in-house. Collaborations with start-ups, universities and even competitors are therefore becoming increasingly important. Roche maintains a global network of research partnerships with leading academic institutions. Bayer has established an accelerator programme for promising biotech start-ups. Merck operates innovation hubs in various technology centres worldwide.

However, these collaboration models require new leadership skills and organisational structures. Dealing with intellectual property in collaborative environments presents many companies with challenges. Pfizer has set up specialist teams for the management of research partnerships. Novartis uses crowdsourcing platforms to solve complex scientific problems. Johnson & Johnson runs a venture capital programme that identifies promising technologies at an early stage.

Best practice with a AIROI customer

A long-established chemical company with a focus on fine chemicals recognised the need to fundamentally transform its business model in order to survive in increasingly intense global competition. transruptions coaching initially focused on developing a clear vision for the future, supported by the entire executive board, which served as a compass for all subsequent decisions. Together, we identified core competencies that set the company apart from competitors and could serve as the basis for new business areas. The introduction of a systematic trend scouting process made it possible to identify relevant technological developments at an early stage and evaluate them strategically. Particularly valuable was the guidance provided during the integration of an acquired start-up, whose innovative technology had to be harmonised with the existing corporate culture. After two years of intensive collaboration, revenue in the new business area had more than tripled and the company was regarded as an innovation leader in its niche.

Regulatory challenges and their strategic significance

Regulatory requirements in the chemical and pharmaceutical industries are continuously increasing and demand significant resources that must be deployed strategically. The REACH Regulation in Europe has massively expanded the documentation obligations for chemical substances. The FDA and EMA are increasingly harmonising their approval requirements, which accommodates international companies. However, new challenges also arise due to differing national interpretations of shared standards.

Roche has established specialised regulatory intelligence teams to anticipate changes early. Sanofi uses digital systems to manage regulatory documentation. AstraZeneca is investing in technologies to accelerate the preparation of regulatory submissions. These investments are paying off, because delays in approvals mean significant financial losses.

The use of real-world evidence is becoming increasingly important in the approval process. Data from clinical practice complement traditional study results and enable faster approval decisions. Novartis systematically collects data on the efficacy of its medicines in practical use. Pfizer is cooperating with health insurers to collect healthcare data. Bristol Myers Squibb uses electronic health records for post-marketing studies.

My AIROI Analysis

The transformation of the chemical and pharmaceutical industry is at a critical turning point, presenting decision-makers with far-reaching strategic choices. The convergence of digitalisation, sustainability and personalised therapeutic approaches creates a complex area of tension that overwhelms traditional management approaches. Companies that wish to successfully master these challenges require not only technological competence, but above all the ability to continuously adapt and evolve their organisation. The examples presented in this article clearly show that success in this environment depends on the willingness to question established mindsets and break new ground. PharmaInnovation: Chemistry & Pharma reimagined ultimately means placing people at the centre – both as recipients of improved therapies and as shapers of change within organisations. transruptions coaching support has proven to be a valuable approach in numerous projects to assist management teams with this demanding transformation and provide individual impetus for strategic development. The coming years will determine which companies successfully shape this transformation and which fall behind. The time to act is now, because the course for the future is being set today.

Further links from the text above:

[1] BASF sustainability strategy
[2] Novartis Research and Development
[3] Roche Innovation Hub
[4] European Medicines Agency – Regulatory information
[5] FDA Drug Information Portal
[6] European Federation of Pharmaceutical Industries

For more information and if you have any questions, please contact Contact us or read more blog posts on the topic Artificial intelligence here.

How useful was this post?

Click on a star to rate it!

Average rating 4.4 / 5. Vote count: 431

No votes so far! Be the first to rate this post.

Spread the love

Leave a comment